Case Report
Localized Subcutaneous Acute Febrile Neutrophilic Dermatosis in a Dog
Table 1
Protocol of the administered drugs during hospitalization of the dog. All listed drugs were administered from the day of presentation onwards, unless mentioned otherwise.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baytril 2.5%, Provet AG, Lyssach, Switzerland; Augmentin Adult, Glaxosmithkline, Muenchenbuchsee, Switzerland; Clavaseptin, Vetoquinol AG, Ittigen, Switzerland; Metronidazol B. Braun, B. Braun Medical AG, Sempach, Switzerland; Dexatat, Dr. E. Graeub AG, Bern, Switzerland; Prednisolon Streuli, G. Streuli & Co. AG, Uznach, Switzerland; Sintenyl i.v. 0.5 mg, Sintetica S.A., Mandrisio, Switzerland; Ketasol, Dr. E. Graeub AG, Bern, Switzerland; Temgesic, Essex Pharma GmbH, Munich, Germany; Tramadol-Mepha 50 retard, Mepha Pharma AG, Aesch, Switzerland; Omeprazol-Teva, Teva Pharma AG, Aesch, Switzerland; Ulcogant Suspension, Merck Serono GmbH, Darmstadt, Germany; Paspertin, Abbott, Altishofen, Switzerland; Anzemet, Sanofi-Aventis; Meyrin, Switzerland; Plasma-Lyte A, Baxter AG, Volketswil, Switzerland. |